TW200640924A - VEGF-R2 inhibitors and methods - Google Patents

VEGF-R2 inhibitors and methods

Info

Publication number
TW200640924A
TW200640924A TW095106022A TW95106022A TW200640924A TW 200640924 A TW200640924 A TW 200640924A TW 095106022 A TW095106022 A TW 095106022A TW 95106022 A TW95106022 A TW 95106022A TW 200640924 A TW200640924 A TW 200640924A
Authority
TW
Taiwan
Prior art keywords
vegf
inhibitors
methods
compounds
formula
Prior art date
Application number
TW095106022A
Other languages
English (en)
Chinese (zh)
Inventor
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Yvonne Yee Mai Yip
Boyu Ahong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TW200640924A publication Critical patent/TW200640924A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW095106022A 2005-02-24 2006-02-23 VEGF-R2 inhibitors and methods TW200640924A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
TW200640924A true TW200640924A (en) 2006-12-01

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095106022A TW200640924A (en) 2005-02-24 2006-02-23 VEGF-R2 inhibitors and methods

Country Status (33)

Country Link
US (1) US7666879B2 (enExample)
EP (1) EP1904494B1 (enExample)
JP (1) JP5055136B2 (enExample)
KR (1) KR100904938B1 (enExample)
CN (1) CN101128461B (enExample)
AR (1) AR056186A1 (enExample)
AT (1) ATE490254T1 (enExample)
AU (1) AU2006216710B2 (enExample)
BR (1) BRPI0609047A2 (enExample)
CA (1) CA2599124C (enExample)
CR (1) CR9331A (enExample)
CY (1) CY1111154T1 (enExample)
DE (1) DE602006018615D1 (enExample)
DK (1) DK1904494T3 (enExample)
DO (1) DOP2006000051A (enExample)
EA (1) EA011691B1 (enExample)
ES (1) ES2354716T3 (enExample)
HR (1) HRP20100677T1 (enExample)
IL (1) IL184717A (enExample)
MA (1) MA29433B1 (enExample)
MX (1) MX2007010326A (enExample)
NO (1) NO20074666L (enExample)
NZ (2) NZ560402A (enExample)
PE (1) PE20061098A1 (enExample)
PL (1) PL1904494T3 (enExample)
PT (1) PT1904494E (enExample)
RS (1) RS51590B (enExample)
SI (1) SI1904494T1 (enExample)
TN (1) TNSN07323A1 (enExample)
TW (1) TW200640924A (enExample)
UA (1) UA91535C2 (enExample)
WO (1) WO2006091671A1 (enExample)
ZA (1) ZA200707136B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
US8367662B2 (en) * 2007-10-17 2013-02-05 Novartis Ag Organic compounds
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
DK2900238T3 (en) * 2012-09-28 2018-03-12 Univ Vanderbilt CONDENSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS
JP6007339B2 (ja) * 2012-11-29 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ イミダゾピリジン誘導体
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
KR20220112867A (ko) 2013-12-16 2022-08-11 에이비에스 디벨롭먼트 원 인코포레이티드 P2x3 및/또는 p2x2/3 화합물 및 방법
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
JP6612857B2 (ja) * 2014-06-03 2019-11-27 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ ベンゾイミダゾールアナログおよび関連方法
JP6665154B2 (ja) 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体及びその薬学的使用
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2018526452A (ja) * 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Ｄｙｒｋ１ａの小分子抑制剤およびその使用
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
CA3125353A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
CN113382990B (zh) 2019-01-11 2024-11-19 格吕伦塔尔有限公司 取代的吡咯烷酰胺iii
WO2020160074A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
CA3128024A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
WO2020168963A1 (zh) * 2019-02-18 2020-08-27 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
JP7664861B2 (ja) * 2019-06-25 2025-04-18 シノプシー セラピューティクス 眼障害の治療のための化合物
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
WO2025038525A1 (en) * 2023-08-11 2025-02-20 Bioventures, Llc Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506880A (ja) 1996-03-15 2000-06-06 ゼネカ・リミテッド シンノリン誘導体及びその使用
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
US6916814B2 (en) 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2005530745A (ja) * 2002-05-02 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害剤
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7262199B2 (en) * 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
US7504412B2 (en) 2003-08-15 2009-03-17 Banyu Pharmaceuticals, Co., Ltd. Imidazopyridine derivatives

Also Published As

Publication number Publication date
BRPI0609047A2 (pt) 2010-11-16
PE20061098A1 (es) 2006-10-20
IL184717A0 (en) 2007-12-03
SI1904494T1 (sl) 2011-02-28
MX2007010326A (es) 2007-10-16
CA2599124A1 (en) 2006-08-31
PT1904494E (pt) 2010-12-23
DE602006018615D1 (de) 2011-01-13
AU2006216710B2 (en) 2011-08-11
DK1904494T3 (da) 2011-02-21
NO20074666L (no) 2007-11-09
MA29433B1 (fr) 2008-05-02
JP2008531574A (ja) 2008-08-14
HRP20100677T1 (hr) 2011-01-31
KR100904938B1 (ko) 2009-06-29
KR20070099029A (ko) 2007-10-08
US20090227622A1 (en) 2009-09-10
EP1904494B1 (en) 2010-12-01
CY1111154T1 (el) 2015-06-11
UA91535C2 (en) 2010-08-10
TNSN07323A1 (en) 2008-12-31
PL1904494T3 (pl) 2011-04-29
AR056186A1 (es) 2007-09-26
IL184717A (en) 2011-11-30
RS51590B (sr) 2011-08-31
DOP2006000051A (es) 2006-08-31
US7666879B2 (en) 2010-02-23
WO2006091671A1 (en) 2006-08-31
CA2599124C (en) 2013-08-06
HK1118284A1 (en) 2009-02-06
JP5055136B2 (ja) 2012-10-24
CN101128461A (zh) 2008-02-20
EP1904494A1 (en) 2008-04-02
ATE490254T1 (de) 2010-12-15
EA011691B1 (ru) 2009-04-28
NZ584753A (en) 2011-06-30
ES2354716T3 (es) 2011-03-17
NZ560402A (en) 2010-06-25
CR9331A (es) 2008-03-31
ZA200707136B (en) 2008-11-26
AU2006216710A1 (en) 2006-08-31
CN101128461B (zh) 2010-12-22
EA200701802A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
TW200640924A (en) VEGF-R2 inhibitors and methods
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
PL1761520T3 (pl) Inhibitory kinazy
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
ZA200701137B (en) Triazolophthalazines
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
GB2466912A (en) Compositions and methods for treating lysosomal disorders
TW200624426A (en) BACE inhibitors
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
UA85505C2 (en) Kinase inhibitors
MX2010007543A (es) Inhibidores de iap.